The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective Phentermine is a commonly used weight-loss agent in the United States, but there is a little information about the use of phentermine for patients with obesity taking antipsychotic medications.Methods We gathered 57 patients with obesity taking antipsychotic medications whose phentermine treatment was simultaneous with or after any type of antipsychotic exposure and collected data of clinical information, initial/follow-up anthropometric variables, and adverse events (AEs) for the 6-month study period.Results In total, the mean body weight reduction (BWR) was 4.45 (7.04) kg, and the mean BWR percent (BWR%) was 3.92% (6.96%) at 6 months. Based on the response to phentermine, the patients were classified into two groups: the responder (n=25; BWR% ≥5%) and nonresponder (n=32; BWR% <5%) groups. The responder group’s mean BWR and BWR% were 10.13 (4.43) kg and 9.35% (4.09%), respectively, at 6 months. The responders had higher rates of anticonvulsant combination therapy (ACT; responder, 72.0% vs. non-responder, 43.8%; p=0.033) and a shorter total antipsychotic exposure duration (responder, 23.9 [16.9] months vs. non-responder, 37.2 [27.6] months; p= 0.039). After adjusting age, sex, and initial body weight, ACT maintained a significant association with phentermine response (odds ratio=3.840; 95% confidence interval: 1.082–13.630; p=0.037). In the final cohort, there was no report of adverse or new-onset psychotic symptoms, and the common AEs were sleep disturbances, dry mouth, and dizziness.Conclusion Overall, phentermine was effective and tolerable for patients with obesity taking antipsychotic medications, and ACT (predominantly topiramate) augmented the weight-loss effect of phentermine.
Abstract
Objective Phentermine is a commonly used weight-loss agent in the United States, but there is a little information about the use of phentermine for patients with obesity taking antipsychotic medications.Methods We gathered 57 patients with obesity taking antipsychotic medications whose phentermine treatment was simultaneous with or after any type of antipsychotic exposure and collected data of clinical information, initial/follow-up anthropometric variables, and adverse events (AEs) for the 6-month study period.Results In total, the mean body weight reduction (BWR) was 4.45 (7.04) kg, and the mean BWR percent (BWR%) was 3.92% (6.96%) at 6 months. Based on the response to phentermine, the patients were classified into two groups: the responder (n=25; BWR% ≥5%) and nonresponder (n=32; BWR% <5%) groups. The responder group’s mean BWR and BWR% were 10.13 (4.43) kg and 9.35% (4.09%), respectively, at 6 months. The responders had higher rates of anticonvulsant combination therapy (ACT; responder, 72.0% vs. non-responder, 43.8%; p=0.033) and a shorter total antipsychotic exposure duration (responder, 23.9 [16.9] months vs. non-responder, 37.2 [27.6] months; p= 0.039). After adjusting age, sex, and initial body weight, ACT maintained a significant association with phentermine response (odds ratio=3.840; 95% confidence interval: 1.082–13.630; p=0.037). In the final cohort, there was no report of adverse or new-onset psychotic symptoms, and the common AEs were sleep disturbances, dry mouth, and dizziness.Conclusion Overall, phentermine was effective and tolerable for patients with obesity taking antipsychotic medications, and ACT (predominantly topiramate) augmented the weight-loss effect of phentermine.
참고문헌 (45)
- Bauer UE, "Prevention of chronic disease in the 21st century : elimination of the leading preventable causes of premature death and disability in the USA", Lancet, 384, pp.45~52 (2014)
- GBD 2015 Obesity Collaborators, "Health effects of overweight and obesity in 195 countries over 25 years", N Engl J Med, 377, pp.13~27 (2017)
- Kroeze WK, "H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs", Neuropsychopharmacology, 28, pp.519~526 (2003)
- Nonogaki K, "Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene", Nat Med, 4, pp.1152~1156 (1998)
- Dietrich MO, "Limitations in anti-obesity drug development : the critical role of hunger-promoting neurons", Nat Rev Drug Discov, 11, pp.675~691 (2012)
- Lett TA, "Pharmacogenetics of antipsychotic-induced weight gain : review and clinical implications", Mol Psychiatry, 17, pp.242~266 (2012)
- Farr OM, "Leptin applications in 2015 : what have we learned about leptin and obesity?", Curr Opin Endocrinol Diabetes Obes, 22, pp.353~359 (2015)
- Flak JN, "Minireview : CNS mechanisms of leptin action", Mol Endocrinol, 30, pp.3~12 (2016)
- Gruzdeva O, "Leptin resistance : underlying mechanisms and diagnosis", Diabetes Metab Syndr Obes, 12, pp.191~198 (2019)
- Virkkunen M, "Decrease of energy expenditure causes weight increase in olanzapine treatment-a case study", Pharmacopsychiatry, 35, pp.124~126 (2002)
- Procyshyn RM, "Clozapine’s effects on body weight and resting metabolic rate : a case series", Schizophr Res, 66, pp.159~162 (2004)
- Fountaine RJ, "Increased food intake and energy expenditure following administration of olanzapine to healthy men", Obesity(Silver Spring), 18, pp.1646~1651 (2010)
- Gothelf D, "Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia", J Neural Transm(Vienna), 110, pp.545~560 (2003)
- Fernø J, "Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation", PLoS One, 6, pp.e20571~ (2011)
- Munro JF, "Comparison of continuous and intermittent anorectic therapy in obesity", Br Med J, 1, pp.352~354 (1968)
- Langlois KJ, "A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride(Fastin)in the treatment of exogenous obesity", Curr Ther Res Clin Exp, 16, pp.289~296 (1974)
- Li Z, "Meta-analysis : pharmacologic treatment of obesity", Ann Intern Med, 142, pp.532~546 (2005)
- Rothman RB, "Appetite suppressants, cardiac valve disease and combination pharmacotherapy", Am J Ther, 16, pp.354~364 (2009)
- Bray GA, "Drug insight : appetite suppressants", Nat Clin Pract Gastroenterol Hepatol, 2, pp.89~95 (2005)
- 강준구, "Anti-Obesity Drugs: A Review about Their Effects and Safety", Diabetes and Metabolism Journal, 36(1), pp.13~25 (2012), 대한당뇨병학회
- Sletten IW, "Weight reduction with chlorphenetermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy", Curr Ther Res Clin Exp, 9, pp.570~575 (1967)
- WHO Collaborating Center for Drug Statistics Methodology, "Guidelines for ATC Classification and DDD assignment 2015", WHO Collaborating Centre for Drug Statistics Methodology, ~ (2014)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
- Saxon DR, "Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015", Obesity(Silver Spring), 27, pp.1975~1981 (2019)
- Srinagesh MT, "Swithching antipsychotics : a guide to dose equivalents", Current Psychiatry, 20, pp.13~14 (2021)
- Laruelle M, "SPECT imaging of striatal dopamine release after amphetamine challenge", J Nucl Med, 36, pp.1182~1190 (1995)
- Fan X, "D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD", Neurobiol Dis, 26, pp.201~211 (2007)
- Owen R, "Dopamine D2 receptors in substantia nigra in schizophrenia", Brain Res, 299, pp.152~154 (1984)
- Dayabandara M, "Antipsychotic-associated weight gain : management strategies and impact on treatment adherence", Neuropsychiatr Dis Treat, 13, pp.2231~2241 (2017)
- Rothman RB, "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin", Synapse, 39, pp.32~41 (2001)
- Rothman AJ, "The strategic use of gain-and loss-framed messages to promote healthy behavior : how theory can inform practice", J Commun, 56(s1), pp.S202~S220 (2006)
- Compton MT, "Cigarette smoking and overweight", obesity among individuals with serious mental illnesses : a preventive perspective, 2006, pp.14, 212~222
- Alvarez-Jiménez M, "Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders : a systematic critical reappraisal", CNS Drugs, 22, pp.547~562 (2008)
- Pilitsi E, "Pharmacotherapy of obesity : available medications and drugs under investigation", Metabolism, 92, pp.170~192 (2019)
- Shi Q, "Pharmacotherapy for adults with overweight and obesity : a systematic review and network meta-analysis of randomised controlled trials", Lancet, 399, pp.259~269 (2022)
- Lee SH, "Schizophreniform-like psychotic disorder induced by phentermine: a case report", Zhonghua Yi Xue Za Zhi(Taipei), 61, pp.44~47 (1998)
- Mula M, "Topiramate and psychiatric adverse events in patients with epilepsy", Epilepsia, 44, pp.659~663 (2003)
- Hyun-Sic Jo, "Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report", Clinical Psychopharmacology and Neuroscience, 17(1), pp.130~133 (2019), 대한정신약물학회[DOI]
- Sweeting AN, "Management of obesity and cardiometabolic risk-role of phentermine", extended release topiramate, 2014, pp.7, 35~44
- Allison DB, "Controlled-release phentermine", topiramate in severely obese adults: a randomized controlled trial (EQUIP), 2012, pp.20, 330~342
- 곽숙영, "식욕억제제 Phentermine, Phendimetrazine으로 유발된 정신병적 장애 증례군 연구", 생물정신의학, 24(3), pp.134~141 (2017), 대한생물정신의학회[DOI]
- Smith SR, "Multicenter, placebo-controlled trial of lorcaserin for weight management", N Engl J Med, 363, pp.245~256 (2010)
- Fidler MC, "A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults : the BLOSSOM trial", J Clin Endocrinol Metab, 96, pp.3067~3077 (2011)
- O’Neil PM, "Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study", Obesity(Silver Spring), 20, pp.1426~1436 (2012)
- Lean ME, "Sibutramine--a review of clinical efficacy", Int J Obes Relat Metab Disord, 21(Suppl 1), pp.S30~S36 (1997)